Vertex Pharmaceuticals (VRTX) Shares Outstanding (2009 - 2026)

Vertex Pharmaceuticals has reported Shares Outstanding (Entity) for 18 years, with the latest figure at $253.3 million in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) fell 1.15% year-over-year to $253.3 million in Q2 2026; TTM through Jun 2026 was $253.3 million, a 1.15% decrease from a year earlier, with the FY2025 full-year figure at $254.0 million, down 1.15% from the prior year.
• Shares Outstanding (Entity) was $253.3 million for Q2 2026 at Vertex Pharmaceuticals, roughly flat from $254.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $258.3 million in Q1 2024, with the low at $253.3 million in Q2 2026.
• Average Shares Outstanding (Entity) over 5 years is $256.4 million, with a median of $257.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) grew 1.0% in 2022, then dropped 1.47% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $257.0 million in 2022, then increased by 0.27% to $257.7 million in 2023, then slipped by 0.29% to $256.9 million in 2024, then retreated by 1.15% to $254.0 million in 2025, then fell by 0.25% to $253.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $253.3 million (Q2 2026), $254.2 million (Q1 2026), and $254.0 million (Q4 2025), per Business Quant data.